Myew-Ling Toh1, Pierre Miossec. 1. Department of Immunology and Rheumatology, Hôpital Edouard Herriot, Lyon, France.
Abstract
PURPOSE OF REVIEW: To update the knowledge on the contribution of T cells in rheumatoid arthritis, a selection of publications between the end of 2005 and 2006 were reviewed. RECENT FINDINGS: Th17 cells driven by TGF-beta, IL-1, IL-6 and IL-23 challenge previous concepts of 'Th1'-induced rheumatoid arthritis. Other advancements in IL-17 studies include novel concepts on the IL-17 receptor and additional information on the mechanism of IL-17-induced effects. Regulatory T cells fail to control disease due to defective function secondary to the synovial inflammatory milieu. The predominance of pathogenic effector T cells in the presence of impaired T-cell regulatory mechanisms may therefore contribute to rheumatoid arthritis chronicity. Cellular therapies attempt to restore the balance that includes production of immunoregulatory cytokines such as IL-4 or IL-10. Better T-cell-targeted therapies controlling costimulation are in place with purported increased efficacy and durability, including anti-tumour necrosis factor nonresponders. Additional direct and indirect T-cell approaches include antagonism of T-cell-derived cytokines, T-cell activation or B-cell ablation. SUMMARY: A renewed interest in T cells comes from the discovery of Th17 in rheumatoid arthritis and from novel findings on the role of T cells in rheumatoid arthritis induction, chronicity and relapse.
PURPOSE OF REVIEW: To update the knowledge on the contribution of T cells in rheumatoid arthritis, a selection of publications between the end of 2005 and 2006 were reviewed. RECENT FINDINGS: Th17 cells driven by TGF-beta, IL-1, IL-6 and IL-23 challenge previous concepts of 'Th1'-induced rheumatoid arthritis. Other advancements in IL-17 studies include novel concepts on the IL-17 receptor and additional information on the mechanism of IL-17-induced effects. Regulatory T cells fail to control disease due to defective function secondary to the synovial inflammatory milieu. The predominance of pathogenic effector T cells in the presence of impaired T-cell regulatory mechanisms may therefore contribute to rheumatoid arthritis chronicity. Cellular therapies attempt to restore the balance that includes production of immunoregulatory cytokines such as IL-4 or IL-10. Better T-cell-targeted therapies controlling costimulation are in place with purported increased efficacy and durability, including anti-tumour necrosis factor nonresponders. Additional direct and indirect T-cell approaches include antagonism of T-cell-derived cytokines, T-cell activation or B-cell ablation. SUMMARY: A renewed interest in T cells comes from the discovery of Th17 in rheumatoid arthritis and from novel findings on the role of T cells in rheumatoid arthritis induction, chronicity and relapse.
Authors: Ma José Jerez; Miguel Jerez; Coral González-García; Sara Ballester; Ana Castro Journal: J Comput Aided Mol Des Date: 2013-01-08 Impact factor: 3.686
Authors: Juan Li; Bin Wei; Ao Guo; Chang Liu; Shichao Huang; Fang Du; Wei Fan; Chunde Bao; Gang Pei Journal: Proc Natl Acad Sci U S A Date: 2013-04-15 Impact factor: 11.205
Authors: Zhiqiang Xu; Michelle A Hurchla; Hongju Deng; Ozge Uluçkan; Fang Bu; Andrew Berdy; Mark C Eagleton; Emanuela A Heller; Desiree H Floyd; Wessel P Dirksen; Sherry Shu; Yuetsu Tanaka; Soledad A Fernandez; Thomas J Rosol; Katherine N Weilbaecher Journal: J Biol Chem Date: 2008-12-05 Impact factor: 5.157
Authors: Adrienn Angyal; Colt Egelston; Tamás Kobezda; Katalin Olasz; Anna László; Tibor T Glant; Katalin Mikecz Journal: Arthritis Res Ther Date: 2010-03-18 Impact factor: 5.156